Premium
Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes
Author(s) -
Kragelund C,
Thomsen CE,
Bardow A,
Pedersen AM,
Nauntofte B,
Reibel J,
Torpet LA
Publication year - 2003
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1034/j.1601-0825.2003.02892.x
Subject(s) - polypharmacy , oral lichen planus , confounding , medicine , cytochrome p450 , drug , drug metabolism , physiology , case control study , cyp2d6 , metabolism , pharmacology , dermatology
Objective: To study if patients with oral lichen planus (OLP) had a medication profile different from that of a control group without oral mucosal lesions. It was hypothesized that OLP lesions might result from poor drug metabolism (PM) because of genetic variation of the major cytochrome P450‐enzymes (CYPs with a PM‐risk). Subjects and methods: Dental records of 172 OLP patients were reviewed in this cross‐sectional study and 152 sex‐ and age‐matched subjects served as controls. The measures for the drug profiles were medicine type (ATC‐code), mono‐ and polypharmacy, CYP‐enzyme metabolism pattern, and medicine with a potential to induce lichenoid drug eruptions. Results: Fifty per cent of the OLP patients consumed daily medications as compared with 59% of the controls. The OLP patients more frequently consumed medicines metabolized by CYPs with a PM‐risk ( P = 0.03). Furthermore, they consumed more medicine with an inhibitory effect on one or more CYPs than the controls ( P = 0.01). Conclusion: Confounders like sex, age, systemic diseases, drug distribution into the therapeutic classes, and polypharmacy were similar in the two groups; but the OLP patients consumed more drugs metabolized by CYPs with a PM‐risk. The results argue for further investigation of associations between OLP, medication intake and the CYP‐enzyme metabolic pathways.